American journal of translational research最新文献

{"title":"Erratum: Predictive value of lipid levels in coronary heart disease in elderly hypertensive patients.","authors":"Xiumei Li, Jiehua Li","doi":"10.62347/WPVF5438","DOIUrl":"https://doi.org/10.62347/WPVF5438","url":null,"abstract":"<p><p>[This corrects the article on p. 2754 in vol. 17, PMID: 40385059.].</p>","PeriodicalId":7731,"journal":{"name":"American journal of translational research","volume":"18 8","pages":"7520"},"PeriodicalIF":1.8,"publicationDate":"2026-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13590969/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149015245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Challenges and perspectives of non-invasive neurostimulation for cognitive enhancement.","authors":"Chuan Wang, Mengyuan Wang, Jiangshan Wang, Wei Dong, Kai Wang, Gongjun Ji, Ziying Wang, Shuogui Xu","doi":"10.62347/LCSS3123","DOIUrl":"10.62347/LCSS3123","url":null,"abstract":"","PeriodicalId":7731,"journal":{"name":"American journal of translational research","volume":"18 8","pages":"7514-7516"},"PeriodicalIF":1.8,"publicationDate":"2026-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13590998/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149015318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Research advances in the translational application of anti-VEGF combined with subthreshold micropulse laser therapy for refractory diabetic macular edema.","authors":"Degong Wang, Dongdong Wei, Fenfen Zhang, Changhui Liu","doi":"10.62347/ASIA3377","DOIUrl":"10.62347/ASIA3377","url":null,"abstract":"<p><p>Diabetic macular edema (DME) is a leading cause of visual decline in patients with diabetic retinopathy (DR). While intravitreal anti-vascular endothelial growth factor (VEGF) agents have become the first-line treatment, some patients fail to achieve complete resolution or experience recurrent fluid accumulation despite ongoing treatment regimens. This therapeutic resistance defines the difficult entity known as refractory DME, which remains a significant management dilemma in clinical practice. Subthreshold micropulse laser (SML) selectively targets retinal pigment epithelium (RPE) cells, inducing heat shock protein (HSP) expression and modulating inflammatory cytokine release. It exerts a biomodulatory effect while avoiding the photocoagulation scars associated with conventional laser. Translational research on combining anti-VEGF therapy with SML has attracted increasing attention. This narrative review covers the disease characteristics and treatment dilemmas of refractory DME, the therapeutic mechanism of SML, clinical evidence for combination therapy, and related translational research. Future directions, including optimization of individualized treatment strategies and exploration of novel biomarkers, are also discussed.</p>","PeriodicalId":7731,"journal":{"name":"American journal of translational research","volume":"18 8","pages":"7498-7513"},"PeriodicalIF":1.8,"publicationDate":"2026-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13590990/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149015476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum: TRAIL-mediated armA upregulation enhances the drug resistance of <i>Klebsiella pneumoniae</i> by activating the PI3K/AKT/mTOR signaling pathway.","authors":"Bu Wang, Wei Zhang, Jianhua Liu, Hongxia Zhang, Maochen Li, Xiaocui Peng, Zhihua Zhang, Ning Song","doi":"10.62347/LHRN1716","DOIUrl":"https://doi.org/10.62347/LHRN1716","url":null,"abstract":"<p><p>[This corrects the article on p. 6103 in vol. 17, PMID: 40950323.].</p>","PeriodicalId":7731,"journal":{"name":"American journal of translational research","volume":"18 8","pages":"7517-7519"},"PeriodicalIF":1.8,"publicationDate":"2026-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13590965/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149015240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Continuity of care combined with TCM acupoint application improves blood pressure control and quality of life in elderly hypertensive patients: a retrospective study with bootstrap mediation analysis.","authors":"Yan Wang, Xiaoran Yang, Yanni Zheng, Yingchun Wei, Rong Zhao, Wenjing Wang","doi":"10.62347/MHFX6040","DOIUrl":"10.62347/MHFX6040","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the effects of continuity of care combined with Traditional Chinese Medicine (TCM) acupoint application on blood pressure control, metabolic parameters, psychological status, treatment adherence, and quality of life in elderly patients with essential hypertension, and to explore potential mediation pathways using Bootstrap-based multiple mediation analysis.</p><p><strong>Methods: </strong>This retrospective study included 393 elderly patients with essential hypertension (experimental group, n = 209; control group, n = 184) treated between January 2022 and January 2025. The experimental group received a 12-week integrated intervention combining TCM acupoint application and continuity of care in addition to standard antihypertensive therapy. The control group received standard antihypertensive therapy and routine nursing only. Primary outcomes were post-intervention systolic blood pressure (SBP) and SF-36 total score. Secondary outcomes included diastolic blood pressure (DBP), laboratory indices, Self-rating Anxiety Scale (SAS), Self-rating Depression Scale (SDS), Adherence to Refills and Medications Scale (ARMS), and self-management behavior scores.</p><p><strong>Results: </strong>Compared with the control group, the experimental group showed significantly lower post-intervention SBP, DBP, TC, TG, FBG, and CRP (all P < 0.05), as well as significantly lower SAS and SDS scores, lower ARMS scores, and higher SF-36 total scores (all P < 0.001). Consistent intervention effects were observed across age subgroups. Mediation analysis identified self-management behavior, anxiety status, and treatment adherence as candidate mediators; however, none reached statistical significance.</p><p><strong>Conclusion: </strong>The integrated intervention significantly improved multidimensional outcomes in elderly hypertensive patients. The identified mediation pathways are hypothesis-generating and require confirmation in future prospective studies.</p>","PeriodicalId":7731,"journal":{"name":"American journal of translational research","volume":"18 8","pages":"6517-6534"},"PeriodicalIF":1.8,"publicationDate":"2026-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13589836/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149011828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A nomogram for predicting insulin resistance in polycystic ovary syndrome based on serum amino acid profiles and anti-Müllerian hormone.","authors":"Yan Zhao, Haiyang Wang, Cuina Zhang, Hongmei He","doi":"10.62347/YUHO4647","DOIUrl":"10.62347/YUHO4647","url":null,"abstract":"<p><strong>Objectives: </strong>Insulin resistance (IR) worsens metabolic and reproductive outcomes in polycystic ovary syndrome (PCOS). This study aimed to develop and validate a nomogram incorporating serum amino acid profiles and anti-Müllerian hormone (AMH) for predicting IR in PCOS.</p><p><strong>Methods: </strong>A retrospective observational analysis was performed on 434 PCOS patients treated at The Fourth Hospital of Shijiazhuang between January 2022 and January 2026. Patients were classified as IR+ (n=184) or IR- (n=250) using a homeostasis model assessment of insulin resistance (HOMA-IR) cutoff of 2.69 and were chronologically assigned to training (n=259) and validation (n=175) cohorts. Anthropometric parameters, hormone levels and serum amino acid concentrations were measured. Multivariable logistic regression identified independent predictors for nomogram development. Receiver operating characteristic (ROC) analysis, calibration plot, bootstrap resampling and decision curve analysis (DCA) were applied to evaluate the model's performance.</p><p><strong>Results: </strong>Multivariable analysis identified body mass index (odds ratio [OR]=1.357, 95% confidence interval [CI]: 1.180-1.561), waist circumference (OR=1.096, 95% CI: 1.053-1.141), AMH (OR=0.931, 95% CI: 0.879-0.986), leucine (OR=1.028, 95% CI: 1.012-1.044), isoleucine (OR=1.075, 95% CI: 1.045-1.107), valine (OR=1.015, 95% CI: 1.009-1.022) and tyrosine (OR=1.046, 95% CI: 1.004-1.089) as independent predictors. The nomogram demonstrated excellent discrimination in training (area under the curve [AUC]=0.945) and validation (AUC=0.917) cohorts, with good calibration (Hosmer-Lemeshow P=0.554) and clinical utility on DCA.</p><p><strong>Conclusion: </strong>This nomogram, integrating anthropometric measures, serum AMH and four amino acids, provides an accurate tool for the early identification of IR in PCOS.</p>","PeriodicalId":7731,"journal":{"name":"American journal of translational research","volume":"18 8","pages":"7487-7497"},"PeriodicalIF":1.8,"publicationDate":"2026-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13590987/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149015272","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Darbepoetin alfa is more effective than epoetin-β in suppressing hepcidin and improving iron utilization in maintenance hemodialysis patients.","authors":"Jinfeng Tan, Huimin Yan, Xin Li, Yong Chen","doi":"10.62347/ZTJE6136","DOIUrl":"10.62347/ZTJE6136","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to compare the dynamics of serum hepcidin and iron metabolism markers in maintenance hemodialysis patients treated with reconstituted human Erythropoietin-β (EPO-β) and darbepoetin alfa (DA).</p><p><strong>Methods: </strong>This retrospective observational study included 105 patients on maintenance hemodialysis. Of these, 64 were in the EPO-β group (administered 2-3 times weekly) and 41 in the DA group (administered once every two weeks). Serum hepcidin, ferritin, transferrin saturation (TSAT), high-sensitivity C-reactive protein (hs-CRP), serum iron and hemoglobin (Hb) were measured at baseline, at week 8 and at week 12. A correlation analysis was performed. For the repeated measures analysis of variance comparing multiple time points (baseline, week 8 and week 12) between the two groups, Bonferroni post-hoc tests were used to perform pairwise comparisons.</p><p><strong>Results: </strong>Serum hepcidin decreased continuously in both groups during the 12-week treatment duration. At week 12, the DA group exhibited significantly lower hepcidin levels compared with EPO-β group. The Δhepcidin from baseline to week 12 was significantly greater in the DA group. The DA group also showed significant improvements in iron metabolism markers, with a greater decrease in TSAT, and a greater increase in serum iron compared to the EPO-β group. The erythropoiesis-stimulating agents resistance index (ERI) was significantly lower in the DA group than in the EPO-β group. LnΔhepcidin showed a positive correlation with LnΔFerritin, LnΔTSAT, LnΔSerum iron, and LnΔHb. The rates of adverse events were comparable between the two groups.</p><p><strong>Conclusion: </strong>Compared to EPO-β, DA more effectively suppresses hepcidin, improves iron metabolism markers, and achieves higher erythropoietic efficiency, with comparable Hb response rates and safety profiles between the two groups.</p>","PeriodicalId":7731,"journal":{"name":"American journal of translational research","volume":"18 8","pages":"6782-6790"},"PeriodicalIF":1.8,"publicationDate":"2026-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13590678/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149015302","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immunotherapy-combined chemotherapy as first-line treatment for stage IIIB/IV large cell neuroendocrine lung carcinoma.","authors":"Zhuoran Li, Zhixiu Xu, Luonan Wang, Xiaona Mao, Tingting Huo, Cailing Jin","doi":"10.62347/PTPR2634","DOIUrl":"10.62347/PTPR2634","url":null,"abstract":"<p><strong>Objectives: </strong>The optimal first-line treatment for advanced large cell neuroendocrine carcinoma of the lung (LCNEC) remains unclear. This study aimed to comprehensively evaluate and compare the efficacy of different first-line treatment regimens in patients with stage IIIB/IV LCNEC.</p><p><strong>Methods: </strong>A retrospective analysis was performed on 93 patients diagnosed with stage IIIB/IV LCNEC at The First Affiliated Hospital of Henan Medical University from March 2017 to December 2022. Based on the initial therapeutic regimen, patients were divided into three groups: chemotherapy alone (Chemotherapy group, n=55), chemotherapy combined with immunotherapy (Immunotherapy+chemotherapy group, n=23), and epidermal growth factor receptor (EGFR)-targeted therapy (Targeted therapy group, n=15; for EGFR-mutant patients). Efficacy was evaluated using objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), and overall survival (OS).</p><p><strong>Results: </strong>The Chemotherapy group had a median PFS of 4.3 months and a median OS of 12.3 months. The Immunotherapy+chemotherapy group achieved an ORR of 56.5% and a DCR of 91.3%, with a significantly longer median PFS of 10.6 months compared to the Chemotherapy group (P<0.0001). The Targeted therapy group showed a median PFS of 6.9 months and a median OS of 18.8 months. Notably, the median PFS of the Immunotherapy+chemotherapy group was markedly prolonged relative to the Chemotherapy group (P<0.0001).</p><p><strong>Conclusions: </strong>Chemotherapy combined with immunotherapy may be a promising first-line treatment strategy for patients with stage IIIB/IV LCNEC, as it significantly improves PFS compared to chemotherapy alone. Additionally, targeted therapy yields encouraging outcomes in EGFR-mutant patients.</p>","PeriodicalId":7731,"journal":{"name":"American journal of translational research","volume":"18 8","pages":"6723-6734"},"PeriodicalIF":1.8,"publicationDate":"2026-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13590723/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149015305","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predicting venous thromboembolism risk after TACE in hepatocellular carcinoma: a logistic model and nursing protocol development.","authors":"Lina Zhi, Wenjie Sun, Xing Liu","doi":"10.62347/YHZV3462","DOIUrl":"10.62347/YHZV3462","url":null,"abstract":"<p><strong>Objective: </strong>To identify risk factors for venous thromboembolism (VTE) after transcatheter arterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC), and to establish a personalized risk prediction nomogram.</p><p><strong>Methods: </strong>A single-center retrospective analysis was performed on 322 consecutive HCC patients who received TACE at Baoji Central Hospital from December 2020 to December 2024. Patients were categorized into a VTE group (n=54) and a non-VTE group (n=268) based on the occurrence of VTE within 7 days post-procedure. Demographic, clinical, and laboratory data were gathered. Pearson correlation and variance inflation factor analyses were applied to evaluate multicollinearity, while logistic regression was used to identify independent risk factors. A nomogram and dynamic prediction model were developed from regression coefficients to quantify individualized risk and guide a structured five-phase nursing intervention plan.</p><p><strong>Results: </strong>Multivariate analysis revealed that elevated D-dimer (DD) levels (OR=1.006), age ≥60 years (OR=0.361), Child-Pugh class C (OR=0.371), ECOG performance score 1-2 (OR=0.361), and multiple TACE sessions (OR=2.847) were independent predictors of post-TACE VTE (all P<0.05). The nomogram showed good calibration and strong discrimination (AUC=0.828). The decision-curve analysis also showed that it had a good net clinical benefit. The developed nursing protocol incorporates risk assessment, dynamic DD monitoring, early mobilization, hepatic function support, and patient education to facilitate risk management.</p><p><strong>Conclusion: </strong>D-dimer level, age, Child-Pugh classification, ECOG status, and the frequency of TACE are all important factors affecting post-TACE VTE. The suggested prediction model is accurate and useful in clinical practice, offering valuable insights into early VTE risk stratification and perioperative safety assessment.</p>","PeriodicalId":7731,"journal":{"name":"American journal of translational research","volume":"18 8","pages":"7163-7176"},"PeriodicalIF":1.8,"publicationDate":"2026-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13590973/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149015525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sodium-glucose cotransporter 2 inhibitors reduce new-onset heart failure and death after myocardial infarction with a preserved ejection fraction following coronary intervention.","authors":"Lingjuan Li, Aihui Zhang, Suozhu Liang, Haitao Zhang, Hui Xu, Dan Li","doi":"10.62347/WPFV8330","DOIUrl":"10.62347/WPFV8330","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate whether SGLT2is (sodium-glucose cotransporter-2 inhibitors prevent new-onset heart failure (HF) in patients with preserved left ventricular ejection fraction (LVEF) following percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI).</p><p><strong>Methods: </strong>This retrospective cohort study enrolled AMI-PCI patients with LVEF ≥ 50% and no prior HF. Based on discharge medication, patients were assigned to a SGLT2i group (empagliflozin or dapagliflozin 10 mg once daily) or a non-SGLT2i group. After 1:1 propensity score matching (PSM), 115 matched pairs were identified. Fasting glucose, lipid profiles, estimated glomerular filtration rate (eGFR), N-terminal pro-B-type natriuretic peptide (NT-proBNP), high-sensitivity cardiac troponin I (hs-cTnI), and echocardiographic values were assessed within 72 hours post-PCI. The primary outcome was the occurrence of new-onset HF events; secondary outcomes included all-cause mortality, cardiovascular mortality, and major adverse cardiovascular events (MACE). Follow-up period was at least 18 months.</p><p><strong>Results: </strong>SGLT2i significantly reduced new-onset HF events (6.09% vs. 15.65%, P=0.020), all-cause mortality (3.48% vs. 10.43%, P=0.038), cardiovascular mortality (1.74% vs. 9.57%, P=0.010), and MACE (7.83% vs. 18.26%, P=0.019). Multivariable Cox regression confirmed SGLT2i use as an independent protective factor (HR, 0.583; 95% CI, 0.371-0.916; P=0.017).</p><p><strong>Conclusion: </strong>Among patients with AMI undergoing PCI and preserved LVEF, SGLT2 inhibitor use was associated with a significant reduction in new-onset HF events and improved survival outcome.</p>","PeriodicalId":7731,"journal":{"name":"American journal of translational research","volume":"18 8","pages":"7012-7024"},"PeriodicalIF":1.8,"publicationDate":"2026-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13590681/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149015261","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}